Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Gross Margin (2016 - 2017)

Historic Gross Margin for Soleno Therapeutics (SLNO) over the last 3 years, with Q2 2017 value amounting to 4100.0%.

  • Soleno Therapeutics' Gross Margin fell 16500000.0% to 4100.0% in Q2 2017 from the same period last year, while for Jun 2017 it was 0.74%, marking a year-over-year decrease of 112900.0%. This contributed to the annual value of 4.03% for FY2016, which is 459800.0% down from last year.
  • Soleno Therapeutics' Gross Margin amounted to 4100.0% in Q2 2017, which was down 16500000.0% from 21.13% recorded in Q1 2017.
  • In the past 5 years, Soleno Therapeutics' Gross Margin ranged from a high of 77.33% in Q3 2015 and a low of 4100.0% during Q2 2017
  • Moreover, its 3-year median value for Gross Margin was 7.52% (2015), whereas its average is 636.51%.
  • Data for Soleno Therapeutics' Gross Margin shows a peak YoY increase of 279600bps (in 2016) and a maximum YoY decrease of -25273200bps (in 2016) over the last 5 years.
  • Over the past 3 years, Soleno Therapeutics' Gross Margin (Quarter) stood at 6.3% in 2015, then skyrocketed by 444bps to 21.66% in 2016, then plummeted by -19025bps to 4100.0% in 2017.
  • Its last three reported values are 4100.0% in Q2 2017, 21.13% for Q1 2017, and 21.66% during Q4 2016.